News

Volatile compounds released by the bacteria Pseudomonas aeruginosa fuel the growth of a fungal pathogen found in lung infections in cystic fibrosis (CF) patients, according to a study recently published in the American Society for Microbiology (ASM) journal mBio. The study, “Volatile Compounds Emitted by Pseudomonas…

In a new study, researchers at Columbia University Medical Center found that viral infections were associated with pulmonary exacerbations in pediatric patients with cystic fibrosis (CF). They also theorized that viruses might impact the respiratory microbiome, leading to the worsening of clinical outcomes during flares. Results of the study, “…

St. Paul, Minnesota-based RespirTech, specialists in the design and manufacture of Airway Clearance Therapy (ACT) vest devices for persons with lung disorders, recently announced the discovery of a novel way to remotely monitor the treatment of cystic fibrosis (CF) patients. Work leading to the innovations was part…

Nivalis Therapeutics, Inc., recently announced an expanded clinical development plan for N91115, the company’s first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in patients with cystic fibrosis (CF). An independent Data Monitoring Committee (DMC) completed a review of interim safety results from the ongoing…

Huge strides have been made in the treatment and management of cystic fibrosis (CF) in the past several decades. According to the U.S. National Institutes of Health (NIH), in 1962 the predicted median survival for cystic fibrosis patients was about 10 years, with few surviving into their teenage years. By the…

The Cystic Fibrosis Foundation (CF Foundation) honored professionals in the Charlotte, North Carolina, area for their business, community leadership, and philanthropy work at its Sixth Annual STANDOUT Awards banquet, with proceeds from the 2015 event going to further the Foundation’s research, care, and educational programs for cystic fibrosis (CF). A banquet highlight was the…

An innovative research center providing tailored physical activity and exercise regimens for young people with cystic fibrosis (CF) has been launched with support for the Cystic Fibrosis Trust. The center will benefit from the skills of an international team of specialists, led by Professor Craig Williams and Dr. Alan Barker from the University of Exeter, U.K.,…

Better ways of treating chronic lung infections in patients with cystic fibrosis (CF) are likely to result from scientific advances in the understanding of how Pseudomonas aeruginosa bacteria evolve and adapt during infections, according to a recently published review from the University of Liverpool, working in collaboration with the University of York. The review appeared in…

Savara Pharmaceuticals recently announced that it has closed a $20 million Series C financing round, which will be used to advance a pivotal Phase 3 clinical trial of AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic being developed for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis…

Vertex Pharmaceuticals, Inc.  recently announced that 18 nonprofit groups were chosen to receive Cystic Fibrosis (CF) Circle of Care grants for 2016, totaling nearly $1 million. The award, now in its second year, is given to medical, academic, patient, and community organizations aiding the cystic fibrosis (CF) community. Despite recent…